arrow
T

Timothy A. Yap

University of Texas MD Anderson Cancer Center
H指数:77
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Werner解旋酶抑制剂用于高级别微卫星不稳定性实体瘤:一项1期临床试验

2026-09-290
OA
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial

Linavonkibart和pembrolizumab在免疫检查点阻断耐药的晚期实体瘤中的应用: 1期试验

2026-01-130
OAAI
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology

可操作的转录组: 将RNA测序纳入精确肿瘤学的框架

2026-01-050
PRE
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen

CDK2抑制增强了CDK4/6抑制剂在综合乳腺癌PDX模型筛选中的抗肿瘤活性

2025-12-030
OAAI
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

YAP/TEAD抑制剂VT3989在实体瘤中的研究:一项1/2期临床试验

2025-10-190
PRE
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

整合群体药代动力学、药效动力学和安全性的综合分析,以指导ATR抑制剂Tuvusertib在临床开发中的剂量选择

2025-08-210
OAAI
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies

克服激素受体阳性、HER2阴性乳腺癌对CDK4/6抑制剂的耐药性:创新联合疗法与新兴策略

2025-06-140
OAAI
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study

DNA-PK抑制剂AZD7648单药或联合聚乙二醇化脂质体多柔比星用于晚期癌症患者:一项首次人体I/IIa期研究的结果

2025-05-170
OA
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study (vol 40, pg 290, 2022)
2025-02-200
OAAI
Early tolerance and late persistence as alternative drug responses in cancer

早期耐受和晚期持续作为癌症中替代的药物反应

2025-02-030
OA